Bionano Genomics Inc gross margin has been in long-term decline. The average rate of decline per year is -5.3%.
The historical rank and industry rank for Bionano Genomics's Gross Margin % or its related term are showing as below:
BNGO'
s Gross Margin % Range Over the Past 10 Years
Min: -1.8 Med: 30.01 Max: 47.31
Current: -1.8
During the past 8 years, the highestGross Margin % of Bionano Genomics was 47.31%. The lowest was -1.80%. And the median was 30.01%.
BNGO's Gross Margin % is ranked worse than 94.66% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 51.89
vs BNGO: -1.80
Bionano Genomics had a gross margin of -139.07% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Bionano Genomics was -5.30% per year.
Bionano Genomics Gross Margin % Historical Data
The historical data trend for Bionano Genomics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bionano Genomics's Gross Margin %
For the Medical Instruments & Supplies subindustry, Bionano Genomics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionano Genomics's Gross Margin % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Bionano Genomics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Bionano Genomics had a gross margin of -139.07% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Bionano Genomics Gross Margin % Related Terms
Thank you for viewing the detailed overview of Bionano Genomics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BNGO has been successfully added to your 